Lung T1 MRI assessments in children with mild cystic fibrosis lung disease.
T1 mapping
children
cystic fibrosis
lung
lung clearance index
magnetic resonance imaging
pulmonary disease
Journal
Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590
Informations de publication
Date de publication:
02 May 2024
02 May 2024
Historique:
revised:
23
03
2024
received:
16
06
2023
accepted:
19
04
2024
medline:
2
5
2024
pubmed:
2
5
2024
entrez:
2
5
2024
Statut:
aheadofprint
Résumé
Lung T1 MRI is a potential method to assess cystic fibrosis (CF) lung disease that is safe, quick, and widely available, but there are no data in children with mild CF lung disease. Assess the ability of lung T1 MRI to detect abnormalities in children with mild CF lung disease. We performed T1 MRI, multiple breath washout (MBW), chest computed tomography (CT), and spirometry in a cohort of 45 children with mild CF lung disease (6-11 years of age). Despite mean normal ppFEV1 values, the majority of children with CF in this study exhibited mild lung disease evident in lung clearance index (LCI) measured by MBW, chest CT Brody scores, and percent normal lung perfusion (%NLP) measured by T1 MRI. The %NLP correlated with chest CT Brody scores, as did LCI, but %NLP and LCI did not correlate with each other. Analysis of the Brody subscores showed that %NLP and LCI largely correlated with different Brody subscores. T1 MRI can detect mild CF lung disease in children and correlates with chest CT findings. The %NLP from T1 MRI and LCI correlate with different chest CT Brody subscores, suggesting they provide complementary information about CF lung disease.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cystic Fibrosis Foundation
Informations de copyright
© 2024 The Authors. Pediatric Pulmonology published by Wiley Periodicals LLC.
Références
O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373:1891‐1904.
Cystic Fibrosis Foundation Patient Registry 2021 Annual Data Report; 2022.
Turcios NL. Cystic fibrosis lung disease: an overview. Respir Care. 2020;65:233‐251.
Wainwright CE. A new era for cystic fibrosis and cystic fibrosis transmembrane conductance regulator modulator trials in infants. Am J Respir Crit Care Med. 2022;206:1193‐1195.
Robinson PD, Goldman MD, Gustafsson PM. Inert gas washout: theoretical background and clinical utility in respiratory disease. Respiration. 2009;78:339‐355.
Gustafsson PM, De Jong PA, Tiddens HAWM, Lindblad A. Multiple‐breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax. 2007;63:129‐134.
Ellemunter H, Fuchs SI, Unsinn KM, et al. Sensitivity of lung clearance index and chest computed tomography in early CF lung disease. Respir Med. 2010;104:1834‐1842.
Robinson PD, Latzin P, Verbanck S, et al. Consensus statement for inert gas washout measurement using multiple‐ and single‐breath tests. Eur Respir J. 2013;41:507‐522.
Ratjen F, Davis SD, Stanojevic S, et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Respir Med. 2019;7:802‐809.
Goralski JL, Stewart NJ, Woods JC. Novel imaging techniques for cystic fibrosis lung disease. Pediatr Pulmonol. 2021;56(suppl 1):S40‐s54.
Tiddens HAWM. Detecting early structural lung damage in cystic fibrosis. Pediatr Pulmonol. 2002;34:228‐231.
Santyr G, Kanhere N, Morgado F, Rayment JH, Ratjen F, Couch MJ. Hyperpolarized gas magnetic resonance imaging of pediatric cystic fibrosis lung disease. Academic Radiol. 2019;26:344‐354.
Roach DJ, Crémillieux Y, Fleck RJ, et al. Ultrashort echo‐time magnetic resonance imaging is a sensitive method for the evaluation of early cystic fibrosis lung disease. Ann Am Thorac Soc. 2016;13:1923‐1931.
Willmering MM, Roach DJ, Kramer EL, Walkup LL, Cleveland ZI, Woods JC. Sensitive structural and functional measurements and 1‐year pulmonary outcomes in pediatric cystic fibrosis. J Cyst Fibros. 2021;20:533‐539.
Stahl M, Wielpütz MO, Graeber SY, et al. Comparison of lung clearance index and magnetic resonance imaging for assessment of lung disease in children with cystic fibrosis. Am J Respir Crit Care Med. 2017;195:349‐359.
Szczesniak R, Turkovic L, Andrinopoulou ER, Tiddens HAWM. Chest imaging in cystic fibrosis studies: what counts, and can be counted? J Cyst Fibros. 2017;16:175‐185.
Donnola SB, Dasenbrook EC, Weaver D, et al. Preliminary comparison of normalized T1 and non‐contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients. J Cyst Fibros. 2017;16:283‐290.
Stadler A, Jakob PM, Griswold M, Stiebellehner L, Barth M, Bankier AA. T1 mapping of the entire lung parenchyma: influence of respiratory phase and correlation to lung function test results in patients with diffuse lung disease. Magn Reson Med. 2008;59:96‐101.
Triphan SMF, Weinheimer O, Gutberlet M, et al. Echo time‐dependent observed lung T1 in patients with chronic obstructive pulmonary disease in correlation with quantitative imaging and clinical indices. J Magn Reson Imaging. 2021;54:1562‐1571.
Jakob PM, Wang T, Schultz G, Hebestreit H, Hebestreit A, Hahn D. Assessment of human pulmonary function using oxygen‐enhanced T(1) imaging in patients with cystic fibrosis. Magn Reson Med. 2004;51:1009‐1016.
Triphan SMF, Stahl M, Jobst BJ, et al. Echo time‐dependence of observed lung T1 in patients with cystic fibrosis and correlation with clinical metrics. J Magn Reson Imaging. 2020;52:1645‐1654.
Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified Look‐Locker inversion recovery (MOLLI) for high‐resolution T1 mapping of the heart. Magn Reson Med. 2004;52:141‐146.
Dasenbrook EC, Lu L, Donnola S, et al. Normalized T1 magnetic resonance imaging for assessment of regional lung function in adult cystic fibrosis patients‐‐a cross‐sectional study. PLoS One. 2013;8:e73286.
Ma D, Badve C, Sun JEP, et al. Motion robust MR fingerprinting scan to image neonates with prenatal opioid exposure. J Magn Reson Imaging. 2023;59:1758‐1768.
Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement. Am J Respir Crit Care Med. 2019;200:e70‐e88.
Nasr SZ, Sakmar E, Christodoulou E, Eckhardt BP, Streetman DS, Strouse PJ. The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease. Pediatr Pulmonol. 2010;45:440‐449.
Sanders DB, Li Z, Brody AS, Farrell PM. Chest computed tomography scores of severity are associated with future lung disease progression in children with cystic fibrosis. Am J Respir Crit Care Med. 2011;184:816‐821.
Sanders DB, Li Z, Parker‐McGill K, Farrell P, Brody AS. Quantitative chest computerized tomography and FEV(1) equally identify pulmonary exacerbation risk in children with cystic fibrosis. Pediatr Pulmonol. 2018;53:1369‐1377.
Brody AS, Kosorok MR, Li Z, et al. Reproducibility of a scoring system for computed tomography scanning in cystic fibrosis. J Thorac Imaging. 2006;21:14‐21.
National Newborn Screening Report 2000; 2003.
Anagnostopoulou P, Latzin P, Jensen R, et al. Normative data for multiple breath washout outcomes in school‐aged Caucasian children. Eur Respir J. 2020;55:1901302.
Owens CM, Aurora P, Stanojevic S, et al. Lung Clearance Index and HRCT are complementary markers of lung abnormalities in young children with CF. Thorax. 2011;66:481‐488.
Ramsey KA, Rosenow T, Turkovic L, et al. Lung clearance index and structural lung disease on computed tomography in early cystic fibrosis. Am J Respir Crit Care Med. 2016;193:60‐67.
Kentgens AC, Latzin P, Anagnostopoulou P, et al. Normative multiple‐breath washout data in school‐aged children corrected for sensor error. Eur Respir J. 2022;60:2102398.
Rosenow T, Oudraad MCJ, Murray CP, et al. PRAGMA‐CF. A quantitative structural lung disease computed tomography outcome in young children with cystic fibrosis. Am J Respir Crit Care Med. 2015;191:1158‐1165.